利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.024 秒)

    Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
    4.
    发明授权
    Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients 失效
    抗T-BAM（CD40-L）单克隆抗体5C8治疗非移植受者再灌注损伤的治疗应用

    公开(公告)号：US06340459B1

    公开(公告)日：2002-01-22

    申请号：US08637323

    申请日：1996-04-22

    申请人： Michael J. Yellin ,  Seth Lederman ,  Leonard Chess

    发明人： Michael J. Yellin ,  Seth Lederman ,  Leonard Chess

    IPC分类号： A61K39395

    CPC分类号： G01N33/576 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70575 ,  C07K14/70578 ,  C07K16/2875 ,  C07K16/2878 ,  C07K2317/73 ,  G01N33/5047 ,  G01N33/505 ,  G01N33/6863 ,  G01N2333/70578 ,  Y02A50/401

    摘要： Activation of cells bearing CD40 on their cell surface by CD40 ligand is inhibited by contacting the cells with an agent capable of inhibiting interaction between CD40 ligand and the cells, in an amount effective to inhibit activation of the cells. Activation of cells bearing CD40 on their surface by CD40 ligand in a subject is inhibited by administering to the subject an agent capable of inhibiting interaction between CD40 ligand and the cells, in an amount effective to inhibit activation of the cells. Reperfusion injury, in an non-transplant recipient, is a condition associated with CD40 ligand-induced activation of CD40-bearing cells. Therefore, reperfusion injury can be treated by the administration of anti-human CD40L monoclonal antibodies, such as those described herein (e.g. 5c8 mAb).

    摘要翻译： 通过使细胞与能够抑制CD40配体和细胞之间的相互作用的试剂以有效抑制细胞活化的量接触来抑制CD40配体在其细胞表面上带有CD40的细胞的活化。 通过向受试者施用能够抑制CD40配体和细胞之间的相互作用的试剂，以有效抑制细胞活化的量来抑制受试者中CD40配体在其表面上带有CD40的细胞的活化。 在非移植受体中的再灌注损伤是与CD40配体诱导的携带CD40的细胞的活化相关的病症。 因此，可以通过施用抗人CD40L单克隆抗体（例如本文所述的那些（例如5c8mAb））来治疗再灌注损伤。

    Soluble forms of the T cell surface protein CD4
    8.
    发明授权
    Soluble forms of the T cell surface protein CD4 失效
    T细胞表面蛋白CD4的可溶形式

    公开(公告)号：US5126433A

    公开(公告)日：1992-06-30

    申请号：US114244

    申请日：1987-10-23

    申请人： Paul J. Maddon ,  Leonard Chess ,  Richard Axel ,  Robin Weiss ,  Dan R. Littman ,  J. Steven McDougal

    发明人： Paul J. Maddon ,  Leonard Chess ,  Richard Axel ,  Robin Weiss ,  Dan R. Littman ,  J. Steven McDougal

    IPC分类号： A61K38/00 ,  C07K14/725 ,  C07K14/73 ,  C12Q1/70

    CPC分类号： C12Q1/703 ,  C07K14/70514 ,  A61K38/00

    摘要： A single-stranded nucleic acid molecule which encodes an amino acid sequence comprising at least a portion of a T4 glycoprotein is provided. Additionally, amino acid sequences which comprise at least a portion of a T4 glycoprotein and are useful as a prophylaxis for treating a subject with acquired immune deficiency syndrome are provided. These amino acid sequences, are capable of specifically forming a complex with a human immunodeficiency virus envelope glycoprotein and which are soluble in an aqueous solution. Monoclonal antibodies directed to the water-soluble amino acid sequences of the present invention may be used as vaccines for immunizing a subject against acquired immune deficiency syndrome.

    摘要翻译： 提供编码包含至少一部分T4糖蛋白的氨基酸序列的单链核酸分子。 此外，提供了包含T4糖蛋白的至少一部分并且可用作预防用于治疗获得性免疫缺陷综合征的受试者的氨基酸序列。 这些氨基酸序列能够与人免疫缺陷病毒包膜糖蛋白特异性形成复合物，并且其可溶于水溶液。 可以使用针对本发明的水溶性氨基酸序列的单克隆抗体作为用于免疫受试者免疫获得性免疫缺陷综合征的疫苗。

    Methods to activate or block the HLA-E/Qa-1 restricted CD8+ T cell regulatory pathway to treat immunological disease
    10.
    发明申请
    Methods to activate or block the HLA-E/Qa-1 restricted CD8+ T cell regulatory pathway to treat immunological disease 审中-公开
    激活或阻断HLA-E / Qa-1限制性CD8 + T细胞调节途径以治疗免疫疾病的方法

    公开(公告)号：US20100267622A1

    公开(公告)日：2010-10-21

    申请号：US12583723

    申请日：2009-08-24

    申请人： Hong Jiang ,  Leonard Chess

    发明人： Hong Jiang ,  Leonard Chess

    IPC分类号： A61K38/02 ,  C12N5/0783 ,  C12Q1/02 ,  A61P37/00 ,  A61P37/06 ,  A61P31/04

    CPC分类号： C07K16/2833 ,  A61K39/00 ,  A61K39/0008 ,  A61K2039/5158 ,  A61K2039/57 ,  A61K2039/6043 ,  C07K2317/24 ,  C07K2317/76

    摘要： Methods are provided for inhibiting or enhancing down-regulation of an antigen-activated HLA-E+ T cell by an HLA-E-restricted CD8+ T cell comprising contacting the HLA-E* T cell and CD8+ T cell with an agent which inhibits or enhances, respectively, binding between (i) T cell receptor (TCR) on the surface of the CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of the HLA-E+ T cell, thereby inhibiting or enhancing, respectively, down-regulation of the antigen-activated HLA-E+ T cell. Compositions comprising agents which inhibit or enhance/activate, respectively, binding between (i) T cell receptor (TCR) on the surface of a CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of a HLA-E+ T cell, and assays for identifying such agents, are provided.

    摘要翻译： 提供了通过HLA-E限制性CD8 + T细胞抑制或增强抗原激活的HLA-E + T细胞下调的方法，包括使HLA-E * T细胞和CD8 + T细胞与抑制或增强的 分别在CD8 + T细胞表面上的（i）T细胞受体（TCR）和（ii）由HLA-E在HLA-E + T细胞表面上呈递的自身肽的结合，从而抑制或增强， 分别为抗原激活的HLA-E + T细胞的下调。 组合物包含分别抑制或增强/激活CD8 + T细胞表面上的（i）T细胞受体（TCR）和（ii）HLA-E在HLA- E + T细胞，以及用于鉴定这些试剂的测定。